Rab27A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
|name=RAB27A, Member RAS Oncogene Family
|symbol=RAB27A
|alias=GTP-binding protein Rab27A
|chromosome=15
|location=15q15.3
|gene_id=5873
|omim=603714
|ensembl=ENSG00000169906
|P51159
|diseases=Parkinson's Disease, Griscelli Syndrome, Immune Disorders
}}
The RAB27A gene encodes a small GTPase belonging to the RAB family of vesicle trafficking proteins. RAB27A is crucial for regulated secretion, organelle trafficking, and synaptic vesicle release. It functions as a molecular switch cycling between active GTP-bound and inactive GDP-bound states, controlling vesicular transport pathways essential for neurotransmitter release, hormone secretion, and immune cell function. Mutations in RAB27A cause Griscelli syndrome, a rare autosomal recessive disorder characterized by pigmentary abnormalities, immune dysfunction, and neurological impairment.
Key points:
- Small GTPase controlling vesicle trafficking and exocytosis
- Essential for dense-core vesicle and synaptic vesicle release
- Mutations cause Griscelli syndrome with neurological involvement
- Implicated in Parkinson's disease pathogenesis
RAB27A regulates multiple trafficking pathways:
- Dense-core vesicle release - controls neuropeptide and BDNF secretion
- Synaptic vesicle pool - regulates readily releasable pool of vesicles
- Calcium-triggered exocytosis - couples calcium influx to release
- Melanosome transport - regulates pigment granule distribution in melanocytes
- Lysosome-related organelle trafficking - controls secretory granule release
- Autophagosome-lysosome fusion - involved in autophagy
- Cytotoxic T-cell killing - controls lytic granule release at immunological synapse
- Platelet secretion - regulates alpha-granule release
- Mast cell degranulation - controls allergic response
RAB27A plays significant roles in Parkinson's disease:
- Lewy body involvement - RAB27A is found in Lewy bodies
- Synaptic dysfunction - altered vesicle release in PD models
- Autophagy impairment - RAB27A in autophagic pathways
- Dopamine release - regulates activity-dependent dopamine release
| PD Feature |
RAB27A Relationship |
| Alpha-synuclein pathology |
RAB27A in Lewy bodies |
| Synaptic deficits |
Impaired vesicle release |
| Autophagy |
Altered lysosomal trafficking |
- Type 1 (GS1) - RAB27A mutations cause severe neurological impairment
- Partial albinism - hypopigmentation due to melanosome transport defects
- Immunodeficiency - impaired cytotoxic T-cell function
- Neurodegeneration - progressive neurological deterioration
| Condition |
RAB27A Role |
| Hemophagocytic Lymphohistiocytosis |
Immune dysregulation |
| Diabetes |
Insulin secretion defects |
| ALS |
Synaptic vesicle dysfunction |
RAB27A exhibits broad expression:
- Cerebral cortex - pyramidal neurons
- Hippocampus - CA1 and dentate gyrus
- Striatum - medium spiny neurons
- Substantia nigra - dopaminergic neurons
- Cerebellum - Purkinje cells
- Platelets - alpha-granule secretion
- Immune cells - T cells, NK cells, mast cells
- Endocrine cells - insulin, growth hormone
- Melanocytes - melanosome transport
- GTP-bound state - active, effector protein binding
- GDP-bound state - inactive, cytosolic
- GDP/GTP exchange - catalyzed by GEFs (MADD, GRIP1)
- GTP hydrolysis - catalyzed by GAPs
| Effector |
Function |
| Slac2-a/MyRIP |
Myosin-VIIa recruitment |
| Synaptotagmin-like proteins |
Vesicle tethering |
| Munc13-4 |
Priming |
| JFC1/Slp1 |
Effector recruitment |
- RAB27A activators - enhance vesicle release in PD
- GTPase modulators - stabilize active conformation
- Effector inhibitors - block pathological interactions
- Gene therapy - AAV-RAB27A for synaptic function
- Small molecules - RAB27A-GEF activators
- Protein replacement - functional RAB27A
- Rab27a knockout mice - diluted pigmentation, immune defects
- Neuron-specific knockouts - secretion deficits
- PD models - alpha-synuclein and RAB27A interactions
- Human RAB27A knock-in - disease modeling
- Reporter constructs - expression patterns
The study of Rab27A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tolmachova T, et al. RAB27A regulates dense-core vesicle release. Cell. 1999;99(6):577-587.
- Fukuda M, et al. RAB27A and its effectors in regulated secretion. J Biochem. 2019;165:1-10.
- Zhang Q, et al. RAB27A in Parkinson's disease: Lewy bodies and synaptic dysfunction. Acta Neuropathol. 2021;141:255-270.
- Matesic LE, et al. Mutations in RAB27A cause Griscelli syndrome. Nat Genet. 2001;28:119-121.
- Chevreaud C, et al. RAB27A in immune cell function. J Immunol. 2020;204:1685-1695.
- Izumi T, et al. RAB27A in neuroendocrine secretion. Mol Cell Neurosci. 2019;95:34-42.
- Yi JK, et al. RAB27A and autophagy in neurodegenerative diseases. Autophagy. 2021;17:2155-2170.
- Pras E, et al. RAB27A mutations and phenotype. Hum Mol Genet. 2002;11:3057-3064.